title: Intracoronary abciximab use in patients undergoing PCI at a community hospital: a single operator experience.
abstract: OBJECTIVE
  To evaluate the safety of intracoronary (IC) abciximab during percutaneous coronary intervention (PCI).
  
  
  BACKGROUND
  Adjunctive treatment with glycoprotein IIb/IIIa inhibitors, especially abciximab, during PCI has been shown to improve clinical and procedural outcomes in numerous studies. However, significant bleeding complications exist with its use and this has limited its standard use. Interest has grown in local (IC) use with studies showing safety and long-term effectiveness, especially in patients with high thrombus loads.
  
  
  METHODS
  A retrospective review of records in a database of patients who had PCI by a single operator at the Easton Hospital.
  
  
  RESULTS
  611 patients received IC abciximab, and there were no complications in 610 (98.3%) patients; only 1 had an allergic reaction.
  
  
  CONCLUSIONS
  IC abciximab is safe and has a unique role in the catheterization lab and in patients at high risk of bleeding complications who would benefit from its limited use.
authors.affiliation: Department of Cardiology, Mt. Sinai Medical Center/Bronx VA, Bronx, New York, USA.
authors.forename: Sandeep S
authors.initials: SS
authors.lastname: Patel
authors.forename: Hiralal
authors.initials: H
authors.lastname: Rana
authors.forename: Daniel A N
authors.initials: DA
authors.lastname: Mascarenhas
mesh_terms: D000077284:Abciximab; D000368:Aged; D015906:Angioplasty, Balloon, Coronary / Q000379:methods*; D000911:Antibodies, Monoclonal / Q000009:adverse effects* / Q000627:therapeutic use; D004342:Drug Hypersensitivity / Q000209:etiology; D005260:Female; D006470:Hemorrhage / Q000139:chemically induced*; D006764:Hospitals, Community; D006801:Humans; D007140:Immunoglobulin Fab Fragments / Q000009:adverse effects* / Q000627:therapeutic use; D008297:Male; D008875:Middle Aged; D010975:Platelet Aggregation Inhibitors / Q000009:adverse effects* / Q000627:therapeutic use; D019039:Platelet Glycoprotein GPIIb-IIIa Complex / Q000037:antagonists & inhibitors; D012189:Retrospective Studies; D012307:Risk Factors
chemical_list: D000911:Antibodies, Monoclonal; D007140:Immunoglobulin Fab Fragments; D010975:Platelet Aggregation Inhibitors; D019039:Platelet Glycoprotein GPIIb-IIIa Complex; D000077284:Abciximab